About Inactive histone-lysine N-methyltransferase 2E
Inactive histone-lysine N-methyltransferase 2E (KMT2E) is a protein
from Homo sapiens identified by UniProt accession
Q8IZD2, 1858 residues long.
MolForge cross-references it against 0 known binders and
274 disease associations.
Target properties
| Protein name | Inactive histone-lysine N-methyltransferase 2E |
|---|
| UniProt accession | Q8IZD2 |
|---|
| Gene | KMT2E |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1858 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (274)
Diseases linked to this target (Open Targets).
- O'Donnell-Luria-Rodan syndrome · score 0.75
- Intellectual disability · score 0.59
- neurodegenerative disease · score 0.54
- genetic disorder · score 0.54
- Global developmental delay · score 0.53
- complex neurodevelopmental disorder · score 0.48
- Autism · score 0.46
- autism · score 0.46
- Seizure · score 0.46
- Neurodevelopmental disorder · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IZD2-F1 | alphafold | PREDICTED | 43.98 | — |
Amino-acid sequence (1858 residues)
MSIVIPLGVD TAETSYLEMA AGSEPESVEA SPVVVEKSNS YPHQLYTSSS HHSHSYIGLP YADHNYGARP PPTPPASPPP SVLISKNEVG IFTTPNFDET SSATTISTSE DGSYGTDVTR CICGFTHDDG YMICCDKCSV WQHIDCMGID RQHIPDTYLC ERCQPRNLDK ERAVLLQRRK RENMSDGDTS ATESGDEVPV ELYTAFQHTP TSITLTASRV SKVNDKRRKK SGEKEQHISK CKKAFREGSR KSSRVKGSAP EIDPSSDGSN FGWETKIKAW MDRYEEANNN QYSEGVQREA QRIALRLGNG NDKKEMNKSD LNTNNLLFKP PVESHIQKNK KILKSAKDLP PDALIIEYRG KFMLREQFEA NGYFFKRPYP FVLFYSKFHG LEMCVDARTF GNEARFIRRS CTPNAEVRHE IQDGTIHLYI YSIHSIPKGT EITIAFDFDY GNCKYKVDCA CLKENPECPV LKRSSESMEN INSGYETRRK KGKKDKDISK EKDTQNQNIT LDCEGTTNKM KSPETKQRKL SPLRLSVSNN QEPDFIDDIE EKTPISNEVE MESEEQIAER KRKMTREERK MEAILQAFAR LEKREKRREQ ALERISTAKT EVKTECKDTQ IVSDAEVIQE QAKEENASKP TPAKVNRTKQ RKSFSRSRTH IGQQRRRHRT VSMCSDIQPS SPDIEVTSQQ NDIENTVLTI EPETETALAE IITETEVPAL NKCPTKYPKT KKHLVNEWLS EKNEKTGKPS DGLSERPLRI TTDPEVLATQ LNSLPGLTYS PHVYSTPKHY IRFTSPFLSE KRRRKEPTEN ISGSCKKRWL KQALEEENSA ILHRFNSPCQ ERSRSPAVNG ENKSPLLLND SCSLPDLTTP LKKRRFYQLL DSVYSETSTP TPSPYATPTH TDITPMDPSF ATPPRIKSDD ETCRNGYKPI YSPVTPVTPG TPGNTMHFEN ISSPESSPEI KRRTYSQEGY DRSSTMLTLG PFRNSNLTEL GLQEIKTIGY TSPRSRTEVN RQCPGEKEPV SDLQLGLDAV EPTALHKTLE TPAHDRAEPN SQLDSTHSGR GTMYSSWVKS PDRTGVNFSV NSNLRDLTPS HQLEVGGGFR ISESKCLMQD DTRGMFMETT VFCTSEDGLV SGFGRTVNDN LIDGNCTPQN PPQKKKVSLL EYRKRQREAR KSGSKTENFP LISVSPHASG SLSNNGDGCA SSNDNGEQVD HTASLPLPTP ATVYNATSEE TSNNCPVKDA TASEKNEPEV QWTASTSVEQ VRERSYQRAL LLSDHRKDKD SGGESPCVSC SPSHVQSSPS SHSNHIPQLQ AKGPVPSFSE LMEDPDPENP EPTTTNECPS PDTSQNTCKS PPKMSKPGSP GSVIPAQAHG KIFTKPDPQW DSTVSASEAE NGVHLKTELQ QKQLSNNNQA LSKNHPPQTH VRNSSEQLSQ KLPSVPTKLH CPPSPHLENP PKSSTPHTPV QHGYLSPKPP SQQLGSPYRP HHSQSPQVGT PQREPQRNFY PAAQNLPANT QQATSGTLFT QTPSGQSSAT YSQFNQQSLN STAPPPPPPP PPSSSYYQNQ QPSANFQNYN QLKGSLSQQT VFTSGPNQAL PGTTSQQTVP GHHVTPGHFL PSQNPTIHHQ TAAAVVPPPP PPPPAPGPHL VQQPNSHQQH SVAHVVGPVH AVTPGSHIHS QTAGHHLPPP PPPPGPAPHH HPPPHPSTGL QGLQAQHQHV VNSAPPPPPP PPPSSVLASG HHTTSAQALH HPPHQGPPLF PSSAHPTVPP YPSQATHHTT LGPGPQHQPS GTGPHCPLPV TGPHLQPQGP NSIPTPTASG FCPHPGSVAL PHGVQGPQQA SPVPGQIPIH RAQVPPTFQN NYHGSGWH
Explore Inactive histone-lysine N-methyltransferase 2E with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets